MoonLake Immunotherapeutics
MLTX
27 hedge funds and large institutions have $123M invested in MoonLake Immunotherapeutics in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 25 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
9% more capital invested
Capital invested by funds: $113M → $123M (+$10.6M)
1.19% more ownership
Funds ownership: 95.77% → 96.95% (+1.2%)
40% less funds holding
Funds holding: 45 → 27 (-18)
72% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$28.4M |
| 2 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$4.57M |
| 3 |
6CM
683 Capital Management
New York
|
+$1.99M |
| 4 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$1.62M |
| 5 |
AWG
Alpha Wave Global
New York
|
+$1.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$3.96M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
-$3.96M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$3.68M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.17M |
MLTX Hedge Fund Activity: Q1 2022 in Review
27 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q1 2022, worth a combined $123M — up 9.4% from $113M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of MLTX and 7 opened new positions — a net loss of 18 holders — while 2 trimmed existing stakes and 8 added.
The largest buyer was Cormorant Asset Management, adding an estimated $28.4M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $10M sold.
- 27 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q1 2022, down from 45 in Q4 2021.
- Funds reported $123M of MoonLake Immunotherapeutics stock for Q1 2022, up 9.4% quarter-over-quarter.
- 7 funds opened new MoonLake Immunotherapeutics positions in Q1 2022 and 25 closed out, a net change of -18 holders.
- The largest MoonLake Immunotherapeutics buyer in Q1 2022 was Cormorant Asset Management, an estimated $28.4M added.
- The largest MoonLake Immunotherapeutics seller in Q1 2022 was Adage Capital Partners, an estimated $10M sold.
Based on aggregated 13F filings for Q1 2022.